Group 1 - Value stocks have lost favor as investors focus on high-growth stocks, particularly those linked to the AI industry [1] - There is a notable decline in valuation multiples due to concerns about a potential U.S. recession [1] - Gary Alexander has extensive experience in technology sectors, both on Wall Street and in Silicon Valley, influencing current industry themes [1]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-K __________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____. Commission File Number: 001-3 ...

GoodRx Holdings Inc. GDRX reported fourth-quarter revenue of $198.6 million, up slightly by 1% year over year, missing the management guidance of around $200 million and consensus of $199.75 million.Fiscal year sales of $792.3 million came in below the guidance of around $794 million.The company reported adjusted EPS of 9 cents, up from 8 cents a year ago, missing the consensus of 10 cents.Q4 prescription transactions revenue increased 0.8% to $144.9 million. 2024 prescription transactions revenue increased ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Aubrey Reynolds - Director, IR Wendy Barnes - CEO Chris McGinnis - CFO Conference Call Participants Lisa Gill - J.P. Morgan John Ransom - RJF Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Jenny Cao - Truist Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Steven Valiquette - Mizuho Securities Jay Jin - Morgan Stanley George Hill - Deutsche Bank Allen Lutz - ...

For the quarter ended December 2024, GoodRx Holdings, Inc. (GDRX) reported revenue of $198.58 million, up 1% over the same period last year. EPS came in at $0.09, compared to $0.08 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $199.81 million, representing a surprise of -0.62%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.09.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

GoodRx (GDRX) Q4 2024 Earnings Call February 27, 2025 08:00 AM ET Company Participants Aubrey Reynolds - Director & Head - Investor RelationsWendy Barnes - President & CEOChris McGinnis - CFOLisa Gill - Managing DirectorJohn Ransom - Managing Director, Director of Healthcare ResearchCharles Rhyee - Managing DirectorJenny Cao - Equity Research AssociateScott Schoenhaus - Managing DirectorJay Jin - Equity Research Associate Conference Call Participants Michael Cherny - Senior Managing Director & Senior Resear ...

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.08, delivering a surprise of -11.11%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.GoodRx, which belon ...

Exhibit 99.1 GOODRX REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance SANTA MONICA, Calif. -- (February 27, 2025) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Full Year 2024 Highlights "I am excited to join GoodRx ...

Wall Street analysts forecast that GoodRx Holdings, Inc. (GDRX) will report quarterly earnings of $0.09 per share in its upcoming release, pointing to a year-over-year increase of 12.5%. It is anticipated that revenues will amount to $199.81 million, exhibiting an increase of 1.6% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this p ...

Executive Changes - GoodRx Holdings CFO Karsten Voermann resigned effective January 16, citing personal reasons [1] - The resignation was not due to any disagreement with the company on operations, policies, or practices [2] - Chief Accounting Officer Romin Nabiey will serve as interim CFO while the company searches for a permanent successor [2] - Nabiey will also continue in his current roles as Chief Accounting Officer and Principal Accounting Officer [3] Financial Performance - GoodRx reported an 8% increase in revenue in Q3, driven by a 4% rise in prescription transactions revenue and a 7% increase in monthly active consumers [3] Strategic Initiatives - The company entered the over-the-counter market in October with a new eCommerce service, partnering with contraceptive maker Opill [5] - The eCommerce service is part of a broader strategy to integrate health and wellness brands into the platform, streamlining purchasing and increasing accessibility [5] - GoodRx and partner pharmacies began offering Affirm's pay-over-time option directly to consumers in October, allowing approved consumers to select Affirm for select medications at participating retailers [5] Leadership Vision - Interim CEO Scott Wagner emphasized the company's focus on medicine affordability and access, stating that this strategic approach has enabled GoodRx to gain market share and strengthen its value proposition [4]